Toby Eyre/X
Nov 8, 2024, 15:14
Toby Eyre: R-Ibrutinib vs R-chemo as first line for Metastatic Cell Lymphoma
Toby Eyre, Specialist in Lymphoma CLL and Senior lecturer in University of Oxford, shared the post on X:
“ENRICH Primary analysis.
-4y follow up
-R-Ibrutinib vs R-chemo (BR or RCHOP) 1L MCL
-IR superior PFS to ICT HR 0.69 p=0.003
-Low haem toxicity
-Earlier increased QoL with R-Ibr
-Major benefit seen vs RCHOP subgroup
-1st 1L RCT across any lymphoma (not included CLL) showing non-chemo superior to ICT.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35